Clinical Trials in Ramat Gan, Ramat Gan
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Multiple Myeloma, Refractory
Karyopharm Therapeutics Inc127 enrolled16 locationsNCT04414475
Recruiting
Phase 2Phase 3
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Advanced Melanoma
Eikon Therapeutics740 enrolled77 locationsNCT06697301